{"id":2673,"date":"2020-12-10T09:37:17","date_gmt":"2020-12-10T17:37:17","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=2673"},"modified":"2020-12-21T15:25:15","modified_gmt":"2020-12-21T23:25:15","slug":"safety-and-efficacy-of-the-bnt162b2-mrna-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/12\/10\/safety-and-efficacy-of-the-bnt162b2-mrna-covid-19-vaccine\/","title":{"rendered":"Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine"},"content":{"rendered":"<ul>\n<li>Results of the phase 3 double-blind, randomized, placebo-controlled trial for the BioNTech and Pfizer mRNA vaccine BNT162b2 (n=21,720 in vaccine group, and 21,728 in placebo group) showed a vaccine efficacy of 95% (95% CI 90.3-97.6), with 8 cases of COVID-19 (1 severe case) in the vaccine group and 162 cases (9 severe cases) in the placebo group. Efficacy was similar across subgroups defined by age, sex, race, ethnicity, body-mass index, and presence of co-existing conditions.<\/li>\n<li>Reactogenicity events were common among vaccine recipients, including arm pain, fatigue and headache. Fever (temperature \u226538C) was reported after the second vaccine dose by 16% of participants &lt;55 years old and 11% of participants &gt;55. Few participants in either group had severe or serious adverse events, and the 6 deaths (2 in vaccine group, 4 in placebo group) were determined by investigators not to be related to the vaccine or placebo by investigators.<\/li>\n<li>Participants were included from 152 sites in 6 countries (130 sites in the US). The majority were aged 18-55 (58%), white (83%), and male (51%). 35% were obese and 21% had at least one coexisting condition.<\/li>\n<\/ul>\n<p>Polack et al. (Dec 10, 2020). Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine. New England Journal of Medicine. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2034577\">https:\/\/doi.org\/10.1056\/NEJMoa2034577<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results of the phase 3 double-blind, randomized, placebo-controlled trial for the BioNTech and Pfizer mRNA vaccine BNT162b2 (n=21,720 in vaccine group, and 21,728 in placebo group) showed a vaccine efficacy of 95% (95% CI 90.3-97.6), with 8 cases of COVID-19 (1 severe case) in the vaccine group and 162 cases (9 severe cases) in the&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/12\/10\/safety-and-efficacy-of-the-bnt162b2-mrna-covid-19-vaccine\/\">Read more<\/a><\/div>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-2673","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=2673"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2673\/revisions"}],"predecessor-version":[{"id":2674,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2673\/revisions\/2674"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=2673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=2673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=2673"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=2673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}